These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20445191)

  • 1. Eculizumab and renal transplantation in a patient with CAPS.
    Lonze BE; Singer AL; Montgomery RA
    N Engl J Med; 2010 May; 362(18):1744-5. PubMed ID: 20445191
    [No Abstract]   [Full Text] [Related]  

  • 2. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
    Zimmerhackl LB; Hofer J; Cortina G; Mark W; Würzner R; Jungraithmayr TC; Khursigara G; Kliche KO; Radauer W
    N Engl J Med; 2010 May; 362(18):1746-8. PubMed ID: 20445192
    [No Abstract]   [Full Text] [Related]  

  • 3. Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab.
    Yelnik CM; Miranda S; Mékinian A; Lazaro E; Quéméneur T; Provot F; Frimat M; Morell-Dubois S; Le Guern V; Hachulla E; Costedoat-Chalumeau N; Lambert M
    Blood; 2020 Nov; 136(21):2473-2477. PubMed ID: 32722806
    [No Abstract]   [Full Text] [Related]  

  • 4. Eculizumab and renal transplantation in a patient with catastrophic antiphospholipid syndrome: effect of heparin on complement activation.
    Velik-Salchner C; Lederer W; Wiedermann F
    Lupus; 2011 Jun; 20(7):772. PubMed ID: 21335395
    [No Abstract]   [Full Text] [Related]  

  • 5. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation.
    Lonze BE; Zachary AA; Magro CM; Desai NM; Orandi BJ; Dagher NN; Singer AL; Carter-Monroe N; Nazarian SM; Segev DL; Streiff MB; Montgomery RA
    Am J Transplant; 2014 Feb; 14(2):459-65. PubMed ID: 24400968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab.
    Shapira I; Andrade D; Allen SL; Salmon JE
    Arthritis Rheum; 2012 Aug; 64(8):2719-23. PubMed ID: 22354668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary antiphospholipid syndrome presented as thrombotic microangiopathy in renal transplantation.
    Bada-Bosch T; Redondo B; Sevillano AM; Alonso M; Trujillo H; Auñón P; Polanco N; Rodríguez L; Gonzalez E; Andrés A
    Nefrologia (Engl Ed); 2020; 40(1):108-110. PubMed ID: 31431303
    [No Abstract]   [Full Text] [Related]  

  • 8. Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome.
    Zikos TA; Sokolove J; Ahuja N; Berube C
    J Clin Rheumatol; 2015 Sep; 21(6):311-3. PubMed ID: 26267719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
    Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.
    Guasch A
    Am J Hematol; 2010 Aug; 85(8):551-2. PubMed ID: 20658585
    [No Abstract]   [Full Text] [Related]  

  • 11. Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome.
    Carrara C; Mataj B; Gastoldi S; Ruggenenti P; Sciascia S; Roccatello D
    Front Immunol; 2024; 15():1460317. PubMed ID: 39318635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
    Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation.
    Carr R; Cataland SR
    Ann Hematol; 2013 Jun; 92(6):845-6. PubMed ID: 23154867
    [No Abstract]   [Full Text] [Related]  

  • 15. Eculizumab in renal transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Rabant M; Loupy A; Timsit MO; Anglicheau D
    Transplant Rev (Orlando); 2013 Jul; 27(3):90-2. PubMed ID: 23747093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric Catastrophic Antiphospholipid Syndrome Successfully Treated with Eculizumab.
    Oulego-Erroz I; Martínez-Sáenz de Jubera J; Ocaña-Alcober C; Regueras-Santos L; Ferrero-De la Mano L; Martínez-Badás JP
    Am J Respir Crit Care Med; 2021 Mar; 203(5):640-642. PubMed ID: 33142067
    [No Abstract]   [Full Text] [Related]  

  • 17. Eculizumab therapy.
    Cataland SR
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):438-9. PubMed ID: 24534107
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiphospholipid antibody-associated choroidopathy.
    Silva RA; Moshfeghi DM
    Eye (Lond); 2014 Jun; 28(6):773-4. PubMed ID: 24603416
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment of acute thrombotic microangiopathy by eculizumab after combined lung and kidney transplantation.
    Commereuc M; Karras A; Amrein C; Boussaud V; Sberro-Soussan R; Guillemain R; Bacchi VF; Thervet E
    Transplantation; 2013 Oct; 96(8):e58-9. PubMed ID: 24132114
    [No Abstract]   [Full Text] [Related]  

  • 20. An open label clinical trial of complement inhibition in multifocal motor neuropathy.
    Fitzpatrick AM; Mann CA; Barry S; Brennan K; Overell JR; Willison HJ
    J Peripher Nerv Syst; 2011 Jun; 16(2):84-91. PubMed ID: 21692905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.